cas 2689-69-2|| where to buy Methyl 3-oxotetrahydrothiophene-2-carboxylate

Nombre del producto:Methyl 3-oxotetrahydrothiophene-2-carboxylate

IUPAC Name:methyl 3-oxothiolane-2-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM199155-1g	in stock	ũũ
CM199155-5g	in stock	ƿƃŵ
CM199155-10g	in stock	ȡƛǶ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2689-69-2 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :2689-69-2; Fórmula molecular:C6H8O3S; Punto de fusión:-; Código de sonrisas:COC(=O)C1SCCC1=O; Densidad:

: Número de catálogo:CM199155; Peso molecular:160.19; Punto de ebullición:248.4°C at 760 mmHg; Nº Mdl:MFCD00156156; Almacenamiento:Keep in dark place, store at 2-8°C.

: Tetrahydrothiophenes; Tetrahydrothiophene is a sulfur-containing saturated heterocyclic compound obtained by catalytic hydrogenation of thiophene. After thiophene is reduced to tetrahydrothiophene, it no longer has a conjugated system and aromaticity. Therefore, tetrahydrothiophene shows the properties of general thioethers. Easily oxidized to sulfoxides and sulfones. Tetrahydrothiophene can be used as a raw material for the production of pharmaceuticals, pesticides and photochemicals.

: Nerandomilast; Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.